Nanoparticle-based drug delivery systems, which can overcome the challenges associated with poor aqueous solubility and other harmful side effects of drugs, display potent applications in cataract treatment. Herein, we designed a nanosystem of gold nanoparticles containing resveratrol (RGNPs) as an anti-aging agent to delay cataracts. The spherical RGNPs had a superior ability to inhibit hydrogen peroxide-mediated oxidative stress damage, including reactive oxygen species (ROS) production, malondialdehyde (MDA) generation, and glutathione (GSH) consumption in the lens epithelial cells. Additionally, the present data showed that RGNPs could delay cellular senescence induced by oxidative stress by decreasing the protein levels of p16 and p21, reducing the ratio of BAX/BCL-2 and the senescence-associated secretory phenotype (SASP) in vitro. Moreover, the RGNPs could also clearly relieve sodium selenite-induced lens opacity in a rat cataract model. Our data indicated that cell senescence was reduced and cataracts were delayed upon treatment with RGNPs through activating the Sirt1/Nrf2 signaling pathway. Our findings suggested that RGNPs could serve as an anti-aging ingredient, highlighting their potential to delay cataract development.

Small incision lenticule extraction (SMILE) and femtosecond laser-assisted in situ keratomileusis (FS-LASIK) are frequently used to treat myopia. However, little is known about the impact on recovery of these approaches in the very early postsurgical phase (within 24 h). To compare the efficacy of these two procedures for the treatment of myopia in the early phase after surgery, differences in visual acuity, OSI (objective scattering index), cutoff for modulation transfer function (MTF), and SR (Strehl ratio) between SMILE and FS-LASIK were evaluated at 0, 2, 4 and 24 h postoperatively using two-way analysis of variance (ANOVA). No significant differences between SMILE and FS-LASIK in the MTF cutoff and SR were found (p > 0.05). However, at 2 h and 4 h after surgery, OSI values in the SMILE group were significantly higher than those in the FS-LASIK group, and visual acuity scores in the SMILE group were significantly poorer than those in the FS-LASIK group (p < 0.05). Regarding subjective symptoms, the number of patients complaining of eye dryness, blurred vision, foreign body sensation and eye soreness in the SMILE group were lower than the number in the FS-LASIK group. In conclusion, visual and optical quality outcomes of FS-LASIK for myopia were better than those of SMILE in the very early phase after surgery, a difference that is attributable to the formation of interface haze. ChiCTR1900021451 .

Background: Several planning algorithms have been developed for topography-guided custom ablation treatment (T-CAT), but each has its own deficiencies. The purpose of this study is to demonstrate the potential of a novel mutual comparative analysis (MCA) informed by manifest refraction and corneal topographic data and the patient’s subjective perception in correcting ametropia. Methods: This retrospective review included patients with significant preoperative differences in the power or axis of astigmatism according to the manifest refraction and corneal topographic data (power > 0.75 D and/or axis > 10°). T-CAT planning was designed using MCA. Follow-ups were conducted for at least 6 months. Results: Seventy-nine patients (121 eyes) were included. The mean preoperative deviation in the astigmatic power and axis were 0.72 ± 0.43 D and 20.18 ± 23.68°, respectively. The average oculus residual astigmatism (ORA) was 0.81 ± 0.32 D (range: 0.08–1.66 D). Six months postoperatively, the mean spherical equivalent refraction was 0.04 ± 0.42 D, and the mean cylinder was − 0.27 ± 0.24 D. The mean efficacy and safety indices were 1.10 and 1.15, respectively. The uncorrected distance visual acuity in 92% of the eyes was the same or better than the corrected distance visual acuity. The angle of error was ±5° in 61% of eyes and ± 15° in 84% of eyes. Residual astigmatism was ≤0.5 D in 91% of eyes. Optical quality and photopic contrast sensitivity did not change significantly (p > 0.05), and the scotopic contrast sensitivity decreased at 3, 6, and 12 cpd (p < 0.05). The vertical coma and horizontal coma of the anterior corneal surface significantly decreased postoperatively but increased during follow-up. Conclusions: The MCA demonstrated safety, efficacy, accuracy, predictability, and stability and can be used as a complementary and feasible method for T-CAT.

Radiation-induced cataracts (RIC), a significant cause of blindness, arise from oxidative damage and inflammation in the lens epithelium, and there has been a lack of effective targeted therapeutic drugs in clinic. Here, we proposed and developed a novel approach for prevention and treatment of RIC via multifunctional nanozymes. We first demonstrated activation of the cGAS-STING pathway can drive mitochondrial oxidative stress and cytosolic double-stranded DNA (dsDNA) accumulation in ionizing radiation (IR)-exposed lens epithelial cells (LECs). Accordingly, a nanozyme-based drug delivery system, namely porous CeO₂ loaded with STING inhibitors H-151 (CeO₂@H-151), was developed for RIC prevention and treatment. Importantly, CeO₂@H-151 nanozymes not only decreased reactive oxygen species (ROS) production induced by mitochondrial oxidative injury, but also reduced inflammation caused by increased dsDNA. This can be attributed to the synergistic effect of antioxidant, anti-inflammation and protein homeostasis-preserving of CeO₂@H-151 nanozymes. It also revealed CeO₂@H-151 nanozymes exerted protein homeostasis preservation through H-151 bound to the Cys172 oxidative modification site of PRDX2. This work provides a synergistic nanotherapeutic strategy targeting the cGAS-STING pathway, offering a promising approach for preventing and treating RIC and even other oxidative-inflammatory disorders. Graphical Abstract